Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd.

This study tests a new antibody drug called 611 in 124 Chinese children and adolescents aged 6 to 18 with moderate to severe atopic dermatitis (eczema). The drug targets a protein involved in inflammation. The main goals are to check safety and how the drug moves through the body…

This Phase 3 trial tested a new drug called 611 in 519 Chinese adults with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. The study compared 611 injections to a placebo over 16 weeks, measuring skin clearance a…

This study tested a new medicine called 601 against an existing drug, ranibizumab, for people with vision loss due to a blocked vein in the eye (branch retinal vein occlusion). 351 adults received injections into the eye to reduce swelling and improve sight. The goal was to see i…

This Phase 2 trial tested an experimental drug called 611 in 142 Chinese adults with moderate-to-severe COPD. Participants received either 611 or a placebo as a shot under the skin every two weeks. The study measured changes in lung function and symptom scores over 16 weeks to se…